Blog
RSS FeedPosted by Michael Wonder on 31 Oct 2018
ICER posts draft scoping document for the assessment of siponimod for the treatment of secondary progressive multiple sclerosis
31 October 2018 - Document open to public comment until 20 November 2018. ...
Posted by Michael Wonder on 30 Oct 2018
Institute for Clinical and Economic Review to publish upcoming assessment on treatments for peanut allergy
30 October 2018 - Report will be subject of CTAF meeting in June 2019; open input now being accepted until 15 ...
Posted by Michael Wonder on 26 Oct 2018
Institute for Clinical and Economic Review report finds extended-release treatments for opioid use disorder provide only marginal benefits over generic alternatives, at significantly higher prices
25 October 2018 - ICER report includes value-based annual price ranges for Probuphine, Vivitrol, and CAM2038. ...
Posted by Michael Wonder on 24 Oct 2018
Institute for Clinical and Economic Review ends assessment of canakinumab for atherosclerosis
24 October 2018 - The Institute for Clinical and Economic Review today announced that it will not proceed with its comparative ...
Posted by Michael Wonder on 11 Oct 2018
ICER finds treatments prevent hereditary angioedema attacks, but cost-effectiveness uncertain and sensitive to frequency of attacks
11 October 2018 - As with all treatments for ultra-rare conditions, judgments of overall value require consideration of the broader patient ...
Posted by Michael Wonder on 10 Oct 2018
Institute for Clinical and Economic Review to publish upcoming assessments on treatments for secondary progressive multiple sclerosis, treatment-resistant depression
10 October 2018 - Both reports will be subject of Midwest CEPAC meeting in May 2019. ...
Posted by Michael Wonder on 04 Oct 2018
ICER review highlights the clinical benefits of using anti-androgen therapies to treat earlier stage prostate cancer
4 October 2018 - Midwest CEPAC’s vote on value reflects uncertainty around duration of treatment with anti-androgens. ...
Posted by Michael Wonder on 27 Sep 2018
Paying for value: US state of play
27 September 2018 - Drug pricing in the US is a perennial topic, which is no surprise given the the ...
Posted by Michael Wonder on 25 Sep 2018
ICER releases draft evidence report on biologic treatments for asthma
24 September 2018 - Public comment period now open until 22 October 2018; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 20 Sep 2018
Will CVS Caremark make ICER the American NICE?
20 September 2018 - Rationing of some sort is part and parcel of every healthcare system. Simply put, it refers to ...
Posted by Michael Wonder on 25 Aug 2018
This drug is safe and effective. Wait. Compared with what?
20 August 2018 - Comparative effectiveness research may be the best way to answer questions that patients and physicians face every ...
Posted by Michael Wonder on 25 Aug 2018
ICER report finds evidence inadequate to distinguish the clinical benefits of different anti-androgen therapies for men with non-metastatic castration-resistant prostate cancer
24 August 2018 - Added costs of treating earlier stage disease with all therapies are aligned with their added clinical benefits ...
Posted by Michael Wonder on 23 Aug 2018
ICER releases draft evidence report on long-term treatments for prevention of hereditary angioedema attacks
23 August 2018 - Public comment period now open until 20 September; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 04 Aug 2018
ICER final report highlights limitations in evidence on long-term safety and effectiveness of elagolix for endometriosis, discusses options for insurance coverage criteria
3 August 2018 - Because elagolix’s price aligns with clinical benefit only when compared to no other treatment, insurers may first ...
Posted by Michael Wonder on 04 Aug 2018
ICER updated report on targeted treatments for plaque psoriasis finds guselkumab and risankizumab offer superior health benefit compared with TNFα inhibitors
3 August 2018 - Policy recommendations repeat call for insurers to minimise step therapy requirements on these treatments that are priced ...